Clinical trial results:
A multicenter, double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of an oral contraceptive preparation YAZ (drospirenone 3 mg / ethinylestradiol 20 µg) for 6 treatment cycles in women with moderate acne vulgaris

Summary

EudraCT number	2014-004612-10
Trial protocol	Outside EU/EEA
Global end of trial date	18 May 2010

Results information

Result version number	v1
This version publication date	12 July 2016
First version publication date	05 July 2015

Trial information

Trial identification

Sponsor protocol code	BAY86-5300/91772

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00818519
WHO universal trial number (UTN)	-
Other trial identifiers	Other study ID: 311963

Notes:

Sponsors

Sponsor organisation name	Bayer HealthCare AG
Sponsor organisation address	Kaiser-Wilhelm-Allee, D-51368, Leverkusen, Germany,
Public contact	Therapeutic Area Head, Bayer HealthCare AG, clinical-trials-contact@bayerhealthcare.com
Scientific contact	Therapeutic Area Head, Bayer HealthCare AG, clinical-trials-contact@bayerhealthcare.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 May 2010
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	18 May 2010
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate the efficacy and safety of YAZ (drospirenone 3 milligram [mg] / ethinylestradiol 20 microgram [mcg]) in comparison with placebo in Chinese female subjects with moderate acne vulgaris over 6 treatment cycles.

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent form was read by and explained to all subjects and/or their legally authorized representative. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	23 December 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	China: 179
Worldwide total number of subjects	179
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	6

Adults (18-64 years)	173
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Analyzed: 179 subjects randomized, 173 in the Full Analysis Set (FAS): 87 in YAZ, 86 in placebo groups, 143 in the Per Protocol Set (PPS): 74 in YAZ, 69 in placebo groups.

Pre-assignment

Screening details:

193 subjects screened, 14 failed screening: withdrawal of consent (7), inclusion/exclusion criteria not met (6), subject lost/no further information available (1). Study drug intake was unknown (3) and 3 subjects to whom study drug was never administered (withdrawal of consent or lost to follow-up) were excluded from FAS.

Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	EE20/Drospirenone (YAZ, BAY86-5300)

Arm description:

In the active treatment group, subjects received 24 consecutive days of active tablets followed by 4 consecutive days of inactive tablets. The active tablet contained 3 mg Drospirenone (DRSP) and 20 mcg Ethinyl estradiol (EE).

Arm type	Experimental
Investigational medicinal product name	EE20/Drospirenone (YAZ)
Investigational medicinal product code	BAY86-5300
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received active tablet containing 3 mg DRSP and 20 mcg EE. Subjects received 24 consecutive days of active tablets followed by 4 consecutive days of inactive tablets.

Arm title	Placebo

Arm description:

The subjects of the placebo group received inert but identical-appearing, color-matched tablets.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

The subjects of the placebo group received inert but identical-appearing, color-matched tablets.

Number of subjects in period 1[1]	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo
Started	87	86
Subjects received treatment	87	86
Completed	75	71
Not completed	12	15
Consent withdrawn by subject	2	6
Adverse Event	2	2
Pregnancy	-	1
Subject recovered completely	1	-
Lost to follow-up	4	5
Subject will leave for long time	1	-
Protocol deviation	2	1

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: All randomized subjects who took at least one tablet of study medication and who provided at least one observation after taking of the first tablet were included in the full analysis set and the baseline data was provided for those subjects. Hence, the worldwide number of subjects enrolled in the trial differs from the number of subjects with data reported for the baseline period.

Baseline characteristics

Reporting groups	
Reporting group title	EE20/Drospirenone (YAZ, BAY86-5300)
Reporting group description:	
In the active treatment group, subjects received 24 consecutive days of active tablets followed by 4 consecutive days of inactive tablets. The active tablet contained 3 mg Drospirenone (DRSP) and 20 mcg Ethinyl estradiol (EE).	
Reporting group title	Placebo
Reporting group description:	
The subjects of the placebo group received inert but identical-appearing, color-matched tablets.	

Reporting group values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo	Total
Number of subjects	87	86	173
Age categorical Units: Subjects			

Age continuous			
Age of subjects was derived from birth date entered onto Case Report Form (CRF).			
Units: years			
arithmetic mean	24	23.4	
standard deviation	± 5.8	± 5.4	-
Gender categorical			
Gender categorical			
Units: subjects			
Female	87	86	173

End points

End points reporting groups

Reporting group title	EE20/Drospirenone (YAZ, BAY86-5300)

Reporting group description:

In the active treatment group, subjects received 24 consecutive days of active tablets followed by 4 consecutive days of inactive tablets. The active tablet contained 3 mg Drospirenone (DRSP) and 20 mcg Ethinyl estradiol (EE).

Reporting group title	Placebo

Reporting group description:

The subjects of the placebo group received inert but identical-appearing, color-matched tablets.

Subject analysis set title	Full Analysis Set (FAS)
Subject analysis set type	Full analysis

Subject analysis set description:

The FAS included all randomized subjects who took at least one tablet of study medication and who provided at least one observation after taking of the first tablet. Study drug intake was unknown (3) and 3 subjects to whom study drug was never administered (withdrawal of consent or lost to follow-up) were excluded from FAS.

Subject analysis set title	Per Protocol Analysis Set (PPS)
Subject analysis set type	Per protocol

Subject analysis set description:

The PPS included all subjects in the FAS who met all the eligibility criteria, had no major protocol deviations which might affect the primary target variable, did not take any prohibited medication, had 80 percent (%) or higher overall study drug compliance, and completed a minimum of 5 treatment cycles.

Primary: Percent Change from Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the FAS (Full Analysis Set)

End point title	Percent Change from Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the FAS (Full Analysis Set)[1]

End point description:

Acne lesions were counted by the trained designee over the entire face. All types of lesions were to be identified and separately counted, that is (i.e.), non-inflammatory open and closed comedones, and inflammatory papules, pustules, and nodules. The percent change from Cycle 6 to Baseline was calculated as (total lesion count at Baseline - total lesion count at Cycle 6)/(total lesion count at Baseline)*100, so that improvement is indicated by a larger percent change.

End point type	Primary

End point timeframe:

Cycle 6 (Day 15 +/- 3 days of Treatment Cycle 6) and Baseline

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87[2]	86[3]		
Units: Percent change				
arithmetic mean (standard deviation)	66.79 (± 31.45)	37.71 (± 118.73)		

Notes:

[2] - FAS

[3] - FAS

Statistical analyses

No statistical analyses for this end point

Primary: Percent Change from Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the PPS (Per Protocol Set)

End point title	Percent Change from Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the PPS (Per Protocol Set)[4]

End point description:

Acne lesions were counted by the trained designee over the entire face. All types of lesions were to be identified and separately counted, i.e., non-inflammatory open and closed comedones, and inflammatory papules, pustules, and nodules. The percent change from Cycle 6 to Baseline was calculated as (total lesion count at Baseline - total lesion count at Cycle 6)/(total lesion count at Baseline)*100, so that improvement is indicated by a larger percent change.

End point type	Primary

End point timeframe:

Cycle 6 (Day 15 +/- 3 days of Treatment Cycle 6) and Baseline

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	74[5]	69[6]		
Units: Percent change				
arithmetic mean (standard deviation)	72.63 (± 27.45)	55.56 (± 32.5)		

Notes:

[5] - PPS

[6] - PPS

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Classified as "0" or "1" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Screening Visit

End point title	Percentage of Subjects Classified as "0" or "1" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Screening Visit

End point description:

ISGA scale 0: Normal, clear skin with no evidence of acne vulgaris; 1: Skin is almost clear, few non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving, not pink-red), no nodular lesions; 2: Few inflammatory lesions, little inflammation, some comedones, no nodular lesions; 3: Non-inflammatory lesions predominate, several inflammatory lesions, one small nodular lesion maybe present; 4: Many inflammatory lesions, up to many comedones, up to a few nodular

lesions; 5: Numerous highly inflammatory lesions predominate, many papules and pustules or nodular lesions.

End point type	Secondary

End point timeframe:

Screening visit

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87[7]	86[8]		
Units: Percentage of subjects				
number (not applicable)	0	0		

Notes:

[7] - Full analysis set at screening

[8] - Full analysis set at screening

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Classified as "0" or "1" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 1

End point title	Percentage of Subjects Classified as "0" or "1" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 1

End point description:

ISGA scale 0: Normal, clear skin with no evidence of acne vulgaris; 1: Skin is almost clear, few non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving, not pink-red), no nodular lesions; 2: Few inflammatory lesions, little inflammation, some comedones, no nodular lesions; 3: Non-inflammatory lesions predominate, several inflammatory lesions, one small nodular lesion maybe present; 4: Many inflammatory lesions, up to many comedones, up to a few nodular lesions; 5: Numerous highly inflammatory lesions predominate, many papules and pustules or nodular lesions.

End point type	Secondary

End point timeframe:

Cycle 1 (Day 15 +/- 3 days of Treatment Cycle 1)

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	84[9]	84[10]		
Units: Percentage of subjects				
number (not applicable)	1.2	0		

Notes:

[9] - FAS, all subjects with data for Cycle 1.

[10] - FAS, all subjects with data for Cycle 1.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Classified as "0" or "1" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 3

End point title	Percentage of Subjects Classified as "0" or "1" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 3

End point description:

ISGA scale 0: Normal, clear skin with no evidence of acne vulgaris; 1: Skin is almost clear, few non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving, not pink-red), no nodular lesions; 2: Few inflammatory lesions, little inflammation, some comedones, no nodular lesions; 3: Non-inflammatory lesions predominate, several inflammatory lesions, one small nodular lesion maybe present; 4: Many inflammatory lesions, up to many comedones, up to a few nodular lesions; 5: Numerous highly inflammatory lesions predominate, many papules and pustules or nodular lesions.

End point type	Secondary

End point timeframe:

Cycle 3 (Day 15 +/- 3 days of Treatment Cycle 3)

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	81[11]	81[12]		
Units: Percentage of subjects				
number (not applicable)	2.5	4.9		

Notes:

[11] - FAS, all subjects with data for Cycle 3.

[12] - FAS, all subjects with data for Cycle 3.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Classified as "0" or "1" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 6

End point title	Percentage of Subjects Classified as "0" or "1" on the 6-point ISGA (Investigator Static Global Assessment) Scale at Cycle 6

End point description:

ISGA scale 0: Normal, clear skin with no evidence of acne vulgaris; 1: Skin is almost clear, few non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving, not pink-red), no nodular lesions; 2: Few inflammatory lesions, little inflammation, some comedones, no nodular lesions; 3: Non-inflammatory lesions predominate, several inflammatory lesions, one small nodular lesion maybe present; 4: Many inflammatory lesions, up to many comedones, up to a few nodular lesions; 5: Numerous highly inflammatory lesions predominate, many papules and pustules or nodular lesions.

End point type	Secondary

End point timeframe:

Cycle 6 (Day 15 +/- 3 days of Treatment Cycle 6)

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	73[13]	71[14]		
Units: Percentage of subjects				
number (not applicable)	49.3	18.3		

Notes:

[13] - FAS, all subjects with data for Cycle 6.

[14] - FAS, all subjects with data for Cycle 6.

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change from Cycle 6 to Baseline in Inflammatory Lesion Count (Papules, Pustules, and Nodules), Non-inflammatory Lesion Count

End point title	Percent Change from Cycle 6 to Baseline in Inflammatory Lesion Count (Papules, Pustules, and Nodules), Non-inflammatory Lesion Count

End point description:

Acne lesions were counted by the trained designee over the entire face. All types of lesions were to be identified and separately counted, i.e., non-inflammatory open and closed comedones, and inflammatory papules, pustules, and nodules. The percent change from Cycle 6 to Baseline was calculated as (lesion count at Baseline - lesion count at Cycle 6)/(lesion count at Baseline)*100, so that improvement is indicated by a larger percent change.

End point type	Secondary

End point timeframe:

Cycle 6 (Day 15 +/- 3 days of Treatment Cycle 6) and Baseline

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	75[15]	71[16]		
Units: Percent change				
arithmetic mean (standard deviation)				
Inflammatory lesion count	75.49 (± 28.11)	60.88 (± 29.92)		
Non-inflammatory lesion count	69.27 (± 33.75)	50.24 (± 49.93)		

Notes:

[15] - FAS (due to missing data number of subjects differs from number at Baseline).

[16] - FAS (due to missing data number of subjects differs from number at Baseline).

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change from Cycle 6 to Baseline in Lesion Count of Papules

End point title	Percent Change from Cycle 6 to Baseline in Lesion Count of Papules

End point description:

Acne lesions were counted by the trained designee over the entire face. All papules were to be identified and separately counted. The percent change from Cycle 6 to Baseline was calculated as (papule count at Baseline - papule count at Cycle 6)/(papule count at Baseline)*100, so that improvement is indicated by a larger percent change.

End point type	Secondary

End point timeframe:

Cycle 6 (Day 15 +/- 3 days of Treatment Cycle 6) and Baseline

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	75[17]	71[18]		
Units: Percent change				
arithmetic mean (standard deviation)	72.36 (± 31.32)	55.03 (± 40.19)		

Notes:

[17] - FAS (due to missing data number of subjects differs from number at Baseline).

[18] - FAS (due to missing data number of subjects differs from number at Baseline).

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change from Cycle 6 to Baseline in Lesion Count of Pustules

End point title	Percent Change from Cycle 6 to Baseline in Lesion Count of Pustules

End point description:

Acne lesions were counted by the trained designee over the entire face. All pustules were to be identified and separately counted. The percent change from Cycle 6 to Baseline was calculated as (pustule count at Baseline - pustule count at Cycle 6)/(pustule count at Baseline)*100, so that improvement is indicated by a larger percent change.

End point type	Secondary

End point timeframe:

Cycle 6 (Day 15 +/- 3 days of Treatment Cycle 6) and Baseline

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64[19]	61[20]		
Units: Percent change				
arithmetic mean (standard deviation)	79.88 (± 40.83)	78.15 (± 34.37)		

Notes:

[19] - FAS (due to missing data number of subjects differs from number at Baseline).

[20] - FAS (due to missing data number of subjects differs from number at Baseline).

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change from Cycle 6 to Baseline in Lesion Count of Nodules

End point title	Percent Change from Cycle 6 to Baseline in Lesion Count of Nodules

End point description:

Acne lesions were counted by the trained designee over the entire face. All nodules were to be identified and separately counted. The percent change from Cycle 6 to Baseline was calculated as (nodule count at Baseline - nodule count at Cycle 6)/(nodule count at Baseline)*100, so that improvement is indicated by a larger percent change.

End point type	Secondary

End point timeframe:

Cycle 6 (Day 15 +/- 3 days of Treatment Cycle 6) and Baseline

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32[21]	30[22]		
Units: Percent change				
arithmetic mean (standard deviation)	95.83 (± 18.45)	95 (± 20.13)		

Notes:

[21] - FAS (due to missing data number of subjects differs from number at Baseline).

[22] - FAS (due to missing data number of subjects differs from number at Baseline).

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change from Cycle 6 to Baseline in Lesion Count of Open Comedones

End point title	Percent Change from Cycle 6 to Baseline in Lesion Count of Open Comedones

End point description:

Acne lesions were counted by the trained designee over the entire face. All open comedones were to be identified and separately counted. The percent change from Cycle 6 to Baseline was calculated as (open comedone count at Baseline -open comedone count at Cycle 6)/(open comedone count at Baseline)*100, so that improvement is indicated by a larger percent change.

End point type	Secondary

End point timeframe:

Cycle 6 (Day 15 +/- 3 days of Treatment Cycle 6) and Baseline

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72[23]	69[24]		
Units: Percent change				
arithmetic mean (standard deviation)	24.03 (± 289.46)	38.31 (± 94.52)		

Notes:

[23] - FAS (due to missing data number of subjects differs from number at Baseline).

[24] - FAS (due to missing data number of subjects differs from number at Baseline).

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change from Cycle 6 to Baseline in Lesion Count of Closed comedones

End point title	Percent Change from Cycle 6 to Baseline in Lesion Count of Closed comedones

End point description:

Acne lesions were counted by the trained designee over the entire face. All closed comedones were to be identified and separately counted. The percent change from Cycle 6 to Baseline was calculated as (closed comedone count at Baseline - closed comedone count at Cycle 6)/(closed comedone count at Baseline)*100, so that improvement is indicated by a larger percent change.

End point type	Secondary

End point timeframe:

Cycle 6 (Day 15 +/- 3 days of Treatment Cycle 6) and Baseline

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	75[25]	70[26]		
Units: Percent change				
arithmetic mean (standard deviation)	69.52 (± 42.24)	48.73 (± 61.16)		

Notes:

[25] - FAS (due to missing data number of subjects differs from number at Baseline).

[26] - FAS (due to missing data number of subjects differs from number at Baseline).

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Classified as “Improved” According to the Investigator’s Overall Improvement Rating and on the Subject's Overall Self-Assessment Rating

End point title	Percentage of Subjects Classified as “Improved” According to the Investigator’s Overall Improvement Rating and on the Subject's Overall Self-Assessment Rating

End point description:

The proportion of subjects rated as “improved” comprises those with complete remission, excellent, marked, or moderate improvement according to the Investigator’s Overall Improvement Rating and

those with excellent, good, or fair improvement the Subject's Overall Self-Assessment Rating. No improvement or deterioration (worsening of disease signs and symptoms compared to Baseline in the view of investigator/subject) comprise "not improved" status.

End point type	Secondary

End point timeframe:

At Cycle 6 (Day 15 +/- 3 days of Treatment Cycle 6, 28 days per cycle)

End point values	EE20/Drospirenone (YAZ, BAY86-5300)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	79[27]	73[28]		
Units: Percentage of subjects				
number (not applicable)				
Investigator	93.7	78.1		
Subject	94.9	84.9		

Notes:

[27] - FAS (due to missing data number of subjects differs from number at Baseline).

[28] - FAS (due to missing data number of subjects differs from number at Baseline).

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the date of informed consent signed until last follow-up visit (15 days after the end of the Cycle 6-medication phase)

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	13.0

Reporting groups

Reporting group title	Placebo

Reporting group description:

The subjects of the placebo group received inert but identical-appearing, color-matched tablets.

Reporting group title	EE20/Drospirenone (YAZ, BAY86-5300)

Reporting group description:

In the active treatment group, subjects received 24 consecutive days of active tablets followedby 4 consecutive days of inactive tablets. The active tablet contained 3 mg DRSP and 20 mcg EE.

Serious adverse events	Placebo	EE20/Drospirenone (YAZ, BAY86-5300)	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 86 (0.00%)	0 / 87 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Placebo	EE20/Drospirenone (YAZ, BAY86-5300)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 86 (34.88%)	43 / 87 (49.43%)	
Investigations			
Blood cholesterol increased			
subjects affected / exposed	1 / 86 (1.16%)	3 / 87 (3.45%)	
occurrences (all)	1	4	
Blood potassium decreased			
subjects affected / exposed	1 / 86 (1.16%)	0 / 87 (0.00%)	
occurrences (all)	1	0	
Blood triglycerides increased			

subjects affected / exposed	0 / 86 (0.00%)	2 / 87 (2.30%)	
occurrences (all)	0	2	
Glycosylated haemoglobin increased			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Haemoglobin decreased			
subjects affected / exposed	1 / 86 (1.16%)	0 / 87 (0.00%)	
occurrences (all)	1	0	
Red blood cells urine positive			
subjects affected / exposed	4 / 86 (4.65%)	1 / 87 (1.15%)	
occurrences (all)	7	1	
White blood cells urine positive			
subjects affected / exposed	2 / 86 (2.33%)	2 / 87 (2.30%)	
occurrences (all)	3	2	
White blood cell count decreased			
subjects affected / exposed	1 / 86 (1.16%)	0 / 87 (0.00%)	
occurrences (all)	1	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Fibroadenoma of breast			
subjects affected / exposed	1 / 86 (1.16%)	0 / 87 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 86 (1.16%)	0 / 87 (0.00%)	
occurrences (all)	1	0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 86 (0.00%)	2 / 87 (2.30%)	
occurrences (all)	0	2	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Abdominal pain upper			

subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Abdominal pain			
subjects affected / exposed	0 / 86 (0.00%)	2 / 87 (2.30%)	
occurrences (all)	0	2	
Diarrhoea			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Nausea			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Vomiting			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Toothache			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Reproductive system and breast disorders			
Breast pain			
subjects affected / exposed	2 / 86 (2.33%)	1 / 87 (1.15%)	
occurrences (all)	2	1	
Breast mass			
subjects affected / exposed	9 / 86 (10.47%)	7 / 87 (8.05%)	
occurrences (all)	9	7	
Cervical dysplasia			
subjects affected / exposed	2 / 86 (2.33%)	0 / 87 (0.00%)	
occurrences (all)	2	0	
Fibrocystic breast disease			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Hypomenorrhoea			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Oligomenorrhoea			

subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Menorrhagia			
subjects affected / exposed	0 / 86 (0.00%)	9 / 87 (10.34%)	
occurrences (all)	0	11	
Menstrual disorder			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Metrorrhagia			
subjects affected / exposed	0 / 86 (0.00%)	7 / 87 (8.05%)	
occurrences (all)	0	10	
Menstruation delayed			
subjects affected / exposed	1 / 86 (1.16%)	0 / 87 (0.00%)	
occurrences (all)	1	0	
Vaginal haemorrhage			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	3	
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	3 / 86 (3.49%)	0 / 87 (0.00%)	
occurrences (all)	3	0	
Infections and infestations			
Cervicitis			
subjects affected / exposed	2 / 86 (2.33%)	1 / 87 (1.15%)	
occurrences (all)	2	1	
Nasopharyngitis			
subjects affected / exposed	2 / 86 (2.33%)	4 / 87 (4.60%)	
occurrences (all)	2	4	
Pelvic inflammatory disease			
subjects affected / exposed	1 / 86 (1.16%)	0 / 87 (0.00%)	
occurrences (all)	1	0	
Pneumonia			

subjects affected / exposed	1 / 86 (1.16%)	0 / 87 (0.00%)	
occurrences (all)	1	0	
Papilloma viral infection			
subjects affected / exposed	1 / 86 (1.16%)	0 / 87 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Hyperlipidaemia			
subjects affected / exposed	0 / 86 (0.00%)	1 / 87 (1.15%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Decimal places were automatically truncated if last decimal equals zero.

Notes: